Business
Avidity Biosciences Announces Upcoming Presentations at 2023 MDA Clinical & Scientific Conference
SAN DIEGO, March 13, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA
About this update from Atrium Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, March 13, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting two oral presentations and multiple poster presentations at the 2023 MDA Clinical & Scientific Conference in Dallas, Texas, being held March 19-22, 2023.\n\n \n \n \n \n \n \n\n \nORAL PRESENTATIONS\n March 22, 2023: 10:30 a.m. – 10:45 a.m. CT\nAOC 1020: An Antibody Oligonucleotide Conjugate (AOC) in Development for the Treatment of FSHD March 22, 2023: 11:15 a.m. – 11:30 a.m. CT\nPhase 1/2 Clinical Trial Evaluating the Safety and Pharmacokinetics of AOC 1001 in Adults with Myotonic Dystrophy Type 1: MARINA™ Trial in Progress**Previously reported data from the December 2022 preliminary assessment will be includedPOSTER PRESENTATIONS\n March 19-21, 2023: 6:00 p.m. – 8:00 p.m. CT\nMyotonic Dystrophy, Comorbid Conditions and Healthcare Utilization Based on a 5-Year Comparative Real-World Data AnalysisAOC 1044: An Antibody Oligonucleotide Conjugate as a Novel Therapeutic Approach for DMD Patients Amenable to Exon 44 SkippingBurden of Duchenne Muscular Dystrophy in Patients with Mutations Amenable to Exon 44 Skipping (DMD44)Phase 1/2 Trial Evaluating AOC 1020 Safety and Pharmacokinetics in Adults with Facioscapulohumeral Muscular Dystrophy (FSHD): FORTITUDE™ Trial DesignOnce available, the presentations and posters will be available on the publications page of Avidity's website at https://www.aviditybiosciences.com.\nAbout Avidity\nAvidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity's proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity's advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is currently in Phase 1/2 development with the ongoing MARINA™ and MARINA-OLE™ trials. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is curr...